Scarica l'app Stockscreener
3.70
2.37%
-0.09
Pre-mercato:
3.70
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.79
Aprire:
$3.75
Volume 24 ore:
2,564
Relative Volume:
0.08
Capitalizzazione di mercato:
$3.25M
Reddito:
$61,000
Utile/perdita netta:
$-5.46M
Rapporto P/E:
-0.5657
EPS:
-6.54
Flusso di cassa netto:
$-6.76M
1 W Prestazione:
-0.80%
1M Prestazione:
-3.90%
6M Prestazione:
-4.00%
1 anno Prestazione:
-46.92%
Intervallo 1D:
$3.70
$4.11
Intervallo di 1 settimana:
$3.53
$4.11
Portata 52W:
$3.03
$14.80
Titan Pharmaceuticals Inc De Stock (TTNP) Company Profile
Nome
Titan Pharmaceuticals Inc De
Settore
Industria
Telefono
(650) 244-4990
Indirizzo
400 OYSTER POINT BLVD, SAN FRANCISCO
Confronta TTNP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TTNP
Titan Pharmaceuticals Inc De
|
3.70 | 3.25M | 61,000 | -5.46M | -6.76M | -6.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Titan Pharmaceuticals Inc De Stock (TTNP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2019-06-26 | Iniziato | Maxim Group | Buy |
| 2017-11-10 | Downgrade | ROTH Capital | Buy → Neutral |
Titan Pharmaceuticals Inc De Borsa (TTNP) Ultime notizie
Nordic Pharma Enters $20.8M Eye Medicine Market with Generic Maxitrol Launch via Harrow Partnership - Stock Titan
US Stocks Likely To Open Higher: Expert Says 'The Selling Pressure Is Starting To Be Exhausted' - Benzinga
Titan Pharma Lands Crucial $1M Backing: Inside the Strategic Investment Deal - Stock Titan
Clinical Data: Nika's ITV-1 Drug Demonstrates Breakthrough Effects in Multiple Diseases - Stock Titan
Conduit Pharma Signals Stock Undervalued: Announces $1M Buyback as Phase II Trials Near - Stock Titan
Strategic Board Shake-Up: Ex-Pharma CFO and Former Congressman Join Titan Environmental's Expansion Push - Stock Titan
Failed Merger Forces Vincerx Pharma to Begin Company Wind-Down: What's Next for Investors? - Stock Titan
Arrowhead Pharmaceuticals Expands Team with 34,190 RSU Grants to New Hires - Stock Titan
Rigel Strengthens Biotech Team: Strategic Stock Grants Attract Key Talent - Stock Titan
Strategic $2.5M Investment Values Mental Health Clinic Network at $50M: Major Expansion Ahead - Stock Titan
Key Investor Update: Lexicon Pharma Takes Stage at Elite Needham Healthcare Conference - Stock Titan
Citius Secures Strategic $2M Funding to Accelerate LYMPHIR LaunchKey Details Revealed - Stock Titan
NRx Pharmaceuticals Lands Revenue-Generating Mental Health Clinic in Strategic Veterans Care Push - Stock Titan
Ironwood Pharma Gets 60-Day Window to Resolve Nasdaq Compliance Issue - Stock Titan
Actinium Reveals 3 Breakthrough Programs Targeting Billion-Dollar Markets at Mar-a-Lago Update - Stock Titan
Actinium Expands into $B Market: Expert Reveals Breakthrough Cancer Programs - Stock Titan
$10M Capital Raise: TransCode Therapeutics Accelerates TTX-MC138 Clinical Trials - StockTitan
Titan Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post
Major Shake-up: Universe Pharmaceuticals Announces 40:1 Share ConsolidationWhat It Means For Investors - StockTitan
Plus Therapeutics Scores FDA Recognition for REYOBIQ Cancer DrugMajor Milestone for CNS Treatment - Stock Titan
Generic Drug Alert: ANI Pharmaceuticals Takes On $36M Market With New Alinia Alternative - StockTitan
Shuttle Pharma Raises $5.75M: Strategic Boost for Revolutionary Cancer Treatment Trial - Stock Titan
NRx Pharmaceuticals Readies Major Financial Update: Full Year Results and Strategic Outlook Coming March 17 - Stock Titan
Endo's $99M Strategic Sale: International Pharma Division Goes to Knight Therapeutics - Stock Titan
Acurx Raises $1.1M in Direct Offering to Advance Antibiotics Pipeline - StockTitan
Can This $1.1M Funding Keep Acurx's Antibiotic Development on Track? - StockTitan
Will NovaBay Survive? Crucial Stockholder Vote Could Determine Company's Fate - StockTitan
Can Conduit Pharmaceuticals Keep Its Nasdaq Listing? Critical Deadlines Ahead - Stock Titan
How Will CTT Pharmaceuticals' OTCQB Upgrade Transform Its Market Presence? - StockTitan
Milestone Pharmaceuticals Awards 94,000 Stock OptionsWhat This Means for Shareholder Value - Stock Titan
Elite Pharmaceuticals Triples Manufacturing Potential With High-Speed Facility Launch - StockTitan
When Will ARS Pharmaceuticals Reveal Its 2024 Financial Performance? - Stock Titan
Is Vincerx Pharma Running Out of Options? Merger Deal Collapses as Cash Dwindles - Stock Titan
Can Virpax's Breakthrough Drug Delivery Tech Transform Pain Management Without Opioid Risks? - StockTitan
When Can Investors Hear Milestone Pharma's Next Strategic Update? Key Conference Date Revealed - Stock Titan
Can This New Estée Lauder Partnership Transform How Your Skin Ages? - Stock Titan
Will Universe Pharmaceuticals Survive Nasdaq's Latest Delisting Threat? - StockTitan
Adial's Addiction Treatment Clears Critical FDA Hurdle Ahead of 2025 Phase 3 Trials - Stock Titan
Can KalVista's March Conference Circuit Signal Major Pipeline Updates? - Stock Titan
Will SXTC's Share Consolidation Save Its Nasdaq Listing? Key Dates Revealed - StockTitan
Can This $430M Pharma Merger Create the Next Women's Health Giant? - StockTitan
Can This 1-for-5 Reverse Split Save 60 Degrees Pharma's Nasdaq Status? - StockTitan
Failed Merger: Why HOOKIPA Pharma Walked Away from Poolbeg Deal - Stock Titan
Can CNS Pharmaceuticals' 5 Key Growth Drivers Transform Brain Cancer Treatment? CEO Reveals 2025 Roadmap - Stock Titan
Major Capital Raise: Petros Pharmaceuticals Locks $9.6M Financing DealStrategic Move or Dilution Risk? - Stock Titan
Citius Pharmaceuticals Secures Critical J-Code for LYMPHIR as Cash Reserves Hit $1.1M - StockTitan
Elite Pharma Q3 Results Reveal Sharp Profit Decline: Holiday Delays Impact Performance - StockTitan
Major Lupus Breakthrough? Conduit Teams Up with Charles River for Game-Changing Treatment Study - Stock Titan
Milestone's CARDAMYST Launch Roadmap: Key Details Coming for $1B PSVT Market Opportunity - Stock Titan
Elite Pharmaceuticals (ELTP) Earnings Preview: Q3 Performance & Strategic Roadmap Unveiling Feb 14 - StockTitan
Opioid Use Disorders Market to Reach USD 8.8 Billion by - GlobeNewswire
Titan Pharmaceuticals Inc De Azioni (TTNP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
36.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):